Sage Therapeutics Announces Changes to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company’s board of directors. Geno Germano has assumed the role of Chair of the Board of Directors. Mr. Starr led the early efforts to launch Sage Therapeutics, served as CEO prior to the company’s initial public offering, and served as Chair of the Board since Sage went public in